July 21, 2026
https://finance.yahoo.com/markets/stocks/articles/gaining-800-1-wall-street-103200236.html They waited a year to notice it? They way to late for that in my opinion. I didn’t find any part of the article particularly interesting. The people that got in a year ago must be very happy.
February 21, 2026
“Spotify reported strong user growth in the fourth quarter of 2025. Monthly active users grew 11% from a year ago to 751 million and surpassed a FactSet estimate of 744.7 million. The company said it had its most successful “Spotify… Continue Reading…
January 26, 2026
“…Acumen Pharmaceuticals (ABOS)… With a major catalyst ahead and ABOS shares trading at $1.98, Stifel’s 5-star analyst Paul Matteis thinks now is the right time to make a move… To this end, Matteis rates ABOS a Buy, and his $10 price… Continue Reading…
December 2, 2025
“…Here’s how the apparel retailer did in the period ended Nov. 1 compared with what Wall Street was anticipating, based on a survey of analysts by LSEG: The company’s reported net income for the quarter was $113 million, or $2.36… Continue Reading…
December 1, 2025
Written By Tina Martin Building strong business credit is a foundational step in scaling any company. Whether you’re a solo entrepreneur or leading a growing organization, your business credit profile influences your access to financing, insurance rates, vendor terms, and… Continue Reading…
August 8, 2025
“SoftBank Group’s shares rallied for a fourth straight session. The Japanese giant announced on Thursday that the value of its Vision Funds rose $4.8 billion. A few of SoftBank’s portfolio companies are expected to go public this year…” https://www.cnbc.com/2025/08/08/softbank-group-shares-first-quarter-earnings-beat-estimates.html
September 4, 2024
“…COMPASS Pathways (CMPS)… Morgan Stanley analyst Vikram Purohit, who covers the stock, sees CMPS as presenting a compelling risk-reward opportunity. He highlights the company’s leading clinical program… To this end, Purohit rates CMPS shares an Overweight (i.e. Buy), and his $23 price… Continue Reading…
August 14, 2024
“…Sales for the month reached NT$256.95 billion ($7.9 billion). For the third quarter, analysts project TSMC revenue should grow 37% to NT$747.4 billion, with the July result suggesting TSMC may surpass those expectations…” https://finance.yahoo.com/news/tsmc-sales-grow-45-july-054146804.html
July 31, 2024
“…RegenXBio (RGNX) The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This… Continue Reading…
July 26, 2024
“… …” https://www.cnbc.com/2024/07/12/citigroup-c-earnings-q2-2024.html
Recent Comments